Meta-Analysis of 29 Experiments Evaluating the Effects of Rapamycin on Life Span in the Laboratory Mouse

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 72, Issue 8, 2017, Pages 1024-1032

  Swindell, William R ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

AFT model; Longevity; mTOR; NNT; Proportional hazard

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

AGING; ANIMAL; ANIMAL EXPERIMENT; DRUG EFFECTS; META ANALYSIS; MOUSE; PHYSIOLOGY;

AGING; ANIMAL EXPERIMENTATION; ANIMALS; IMMUNOSUPPRESSIVE AGENTS; MICE; SIROLIMUS;

EID: 85026853627     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glw153     Document Type: Article

References (54)

1. Warner HR. NIA's Intervention Testing Program at 10 years of age. Age. 2015;37:22. doi:10.1007/s11357-015-9761-5
2. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392-395. doi:10.1038/nature08221
3. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66:191-201. doi:10.1093/gerona/glq178
4. Strong R, Miller RA, Astle CM, et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2013;68:6-16. doi:10.1093/gerona/gls070
5. Harrison DE, Strong R, Allison DB, et al. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014;13:273-282. doi:10.1111/acel.12170
6. Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13:468-477. doi:10.1111/acel.12194
7. Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci. 2014;71:4325-4346. doi:10.1007/s00018-014-1677-1
8. Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell. 2012;11:675-682. doi:10.1111/j.1474-9726.2012.00832.x
9. Castillo-Quan JI, Kinghorn KJ, Bjedov I. Genetics and pharmacology of longevity: the road to therapeutics for healthy aging. Adv Genet. 2015;90:1-101. doi:10.1016/bs.adgen.2015.06.002
10. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6:268ra179. doi:10.1126/scitranslmed.3009892
11. Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10:4230-4236. doi:10.4161/cc.10.24.18486
12. Neff F, Flores-Dominguez D, Ryan DP, et al. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Investig. 2013;123:3272-3291. doi:10.1172/jci67674
13. Fok WC, Chen Y, Bokov A, et al. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PloS One. 2014;9:e83988. doi:10.1371/journal.pone.0083988
14. Zhang Y, Bokov A, Gelfond J, et al. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. 2014;69:119-130. doi:10.1093/gerona/glt056
15. Sataranatarajan K, Ikeno Y, Bokov A, et al. Rapamycin increases mortality in db/db mice, a mouse model of type 2 diabetes. J Gerontol A Biol Sci Med Sci. 2016;71:850-857. doi:10.1093/gerona/glv170
16. Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent administration of rapamycin extends the life span of female C57BL/6J mice. J Gerontol A Biol Sci Med Sci. 2016;71:876-881. doi:10.1093/gerona/glw064
17. Swindell WR. Dietary restriction in rats and mice: a meta-analysis and review of the evidence for genotype-dependent effects on lifespan. Ageing Res Rev. 2012;11:254-270. doi:10.1016/j.arr.2011.12.006
18. Garratt M, Nakagawa S, Simons MJ. Comparative idiosyncrasies in life extension by reduced mTOR signalling and its distinctiveness from dietary restriction. Aging Cell. 2016;15:737-743. doi:10.1111/acel.12489
19. Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell. 2015;162:259-270. doi:10.1016/j.cell.2015.06.017
20. Svenson KL, Von Smith R, Magnani PA, et al. Multiple trait measurements in 43 inbred mouse strains capture the phenotypic diversity characteristic of human populations. J Appl Physiol. 2007;102:2369-2378. doi:10.1152/japplphysiol.01077.2006
21. Sundberg JP, Berndt A, Sundberg BA, et al. The mouse as a model for understanding chronic diseases of aging: the histopathologic basis of aging in inbred mice. Pathobiol Aging Age Relat Dis. 2011;1:7119. doi:10.3402/pba.v1i0.7179
22. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533-1537.
23. Collett D. Modelling Survival Data in Medical Research. 1st ed. London: Chapman & Hall; 1994.
24. Cox DR. Regression models and life-tables. J Roy Statist Soc B. 1972;34:187-220.
25. Swindell WR. Accelerated failure time models provide a useful statistical framework for aging research. Exp Gerontol. 2009;44:190-200. doi:10.1016/j.exger.2008.10.005
26. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
27. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
28. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell. 2014;13:616-622. doi:10.1111/acel.12211
29. Strong R, Miller RA, Antebi A, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016. doi:10.1111/acel.12496
30. Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009;2:ra75. doi:1126/scisignal.2000559
31. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:1186/1471-2288-12-9
32. Ziehm M, Thornton JM. Unlocking the potential of survival data for model organisms through a new database and online analysis platform: SurvCurv. Aging Cell. 2013;12:910-916. doi:10.1111/acel.12121
33. Sokal RR. Biometry: the Principles and Practice of Statistics in Biological Research. San Francisco, CA: W. H. Freeman; 1969.
34. Clarke MJ, Stewart LA. Meta-analyses using individual patient data. J Eval Clin Pract. 1997;3:207-212.
35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
36. Anzures-Cabrera J, Higgins JP. Graphical displays for meta-analysis: an overview with suggestions for practice. Res Synth Methods. 2010;1:66-80. doi:10.1002/jrsm.6
37. Wang C, Li Q, Redden DT, Weindruch R, Allison DB. Statistical methods for testing effects on "maximum lifespan". Mech Ageing Dev. 2004;125:629-632. doi:10.1016/j.mad.2004.07.003
38. Miller RA, Nadon NL. Principles of animal use for gerontological research. J Gerontol A Biol Sci Med Sci. 2000;55:B117-B123.
39. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505:612-613.
40. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124. doi:10.1371/journal.pmed.0020124
41. Tardif S, Ross C, Bergman P, et al. Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci. 2015;70:577-587. doi:10.1093/gerona/glu101
42. Kaeberlein M, Creevy KE, Promislow DE. The dog aging project: translational geroscience in companion animals. Mamm Genome. 2016;27:279-288. doi:10.1007/s00335-016-9638-7
43. Liao CY, Rikke BA, Johnson TE, Diaz V, Nelson JF. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell. 2010;9:92-95. doi:10.1111/j.1474-9726.2009.00533.x
44. Rae EA, Brown RE. The problem of genotype and sex differences in life expectancy in transgenic AD mice. Neurosci Biobehav Rev. 2015;57:238-251. doi:10.1016/j.neubiorev.2015.09.002
45. Jamison MG, White JM, Vinson WE, Hinkelmann K. Diallel analysis of growth traits in mice. Genetics. 1975;81:369-376.
46. Lippman ZB, Zamir D. Heterosis: revisiting the magic. Trends Genet. 2007;23:60-66. doi:10.1016/j.tig.2006.12.006
47. Shapira R, Levy T, Shaked S, Fridman E, David L. Extensive heterosis in growth of yeast hybrids is explained by a combination of genetic models. Heredity. 2014;113:316-326. doi:10.1038/hdy.2014.33
48. Sun Y, Guo CY, Wang DD, et al. Transcriptome analysis reveals the molecular mechanisms underlying growth superiority in a novel grouper hybrid (Epinephelus fuscogutatus female symbol x E. lanceolatus male symbol). BMC Genet. 2016;17:24. doi:10.1186/s12863-016-0328-y
49. Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22:2113-2126. doi:10.1002/sim.1461
50. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333:597-600. doi:10.1136/bmj.333.7568.597
51. McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, Kaiser T. Reporting bias in medical research-a narrative review. Trials. 2010;11:37. doi:10.1186/1745-6215-11-37
52. Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation. 2009;87:S23-S26. doi:10.1097/TP.0b013e3181a05b7a
53. Mora S, Manson JE. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Int Med. 2016. doi:10.1001/jamainternmed.2016.26
54. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934. doi:10.1016/j.jacc.2013.11.002